

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RELTON *et al.*Appl. No.: *To Be Assigned* (U.S. Nat'l Phase of  
PCT/US2005/002535; Int'l Filing Date:  
January 28, 2005)Filed: *Herewith* (July 28, 2006)For: **Treatment of Conditions Involving  
Dopaminergic Neuronal Degeneration  
Using Nogo Receptor Antagonists**Confirmation No.: *To Be Assigned*Art Unit: *To Be Assigned*Examiner: *To Be Assigned*

Atty. Docket: 2159.0450001/EJH/SAC

**Authorization to Treat a Reply as Incorporating an  
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN &amp; FOX P.L.L.C.

Shannon A. Carroll, Ph.D.  
Attorney for Applicants  
Registration No. 58,240Date: July 28, 2006  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
492663.1